Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Irbefar - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Irbefar

Approved

STANDARD

Irbefar

Magbro Healthcare Pvt. Ltd.🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: d9c39b7d62c16270
Company: Magbro Healthcare Pvt. Ltd.
Type: Standard

Approval Details

Approval Id: d9c39b7d62c16270
Drug Approval Philippines Name: Irbefar
Product Name: Irbefar
Registration Number: DRP-12740
Brand Name: Irbefar
Generic Name: Irbesartan
Dosage Form: Film-Coated Tablet
Dosage Strength: 150 mg
Manufacturer: Magbro Healthcare Pvt. Ltd.
Importer: Pharmakon Biotec Inc.
Distributor: Pharmakon Biotec Inc.
Issuance Date: 26 October 2022
Expiry Date: 29 September 2027
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

d9c39b7d62c16270

Type

Standard

Back to Philippines FDA Approvals